Tavneos EU Revocation: Data Manipulation Destroys Pivotal Evidence Base, No Near-Term Recovery Path

EU Revokes Tavneos Authorization Over Pivotal Study Breaches

European regulators have revoked the marketing authorization for Amgen's rare disease drug Tavneos in the EU, citing "serious breaches" in its pivotal clinical study. The European Medicines Agency (EMA) found that personnel from ChemoCentryx, the drug's original developer, accessed unblinded efficacy data after the database lock and subsequently re-adjudicated data from nine patients. This manipulation changed the primary analysis from non-significant to statistically significant at week 52. The EMA concluded the study was unreliable, making a positive risk-benefit profile impossible. The FDA is also scrutinizing Tavneos, having requested its voluntary withdrawal due to similar concerns, and the New England Journal of Medicine retracted the study's paper. Amgen, which acquired ChemoCentryx for $3.7 billion, continues to defend the drug.

• The European Medicines Agency (EMA) detailed "serious breaches" in Tavneos' pivotal study, revealing that ChemoCentryx personnel viewed unblinded efficacy data after the database was locked. This occurred after discovering that the primary endpoint of superiority at week 52 had not been demonstrated. Subsequently, data from nine patients were re-adjudicated with knowledge of treatment outcomes, which then altered the primary analysis from non-significant to statistically significant. These critical changes were not disclosed to regulators, and the clinical study report falsely claimed adherence to the unblinding protocol.
• Based on these findings, the European Commission officially revoked Tavneos' marketing authorization across the European Union and European Economic Area countries. The EMA concluded that the entire pivotal study was unreliable, rendering the results submitted in the drug's application "incorrect and misleading." Consequently, the agency determined that no feasible conditions could establish a positive risk-benefit profile for Tavneos, leading to the definitive withdrawal of its market approval in the region.
• Tavneos is facing similar intense regulatory scrutiny in the United States, with the FDA having requested Amgen to voluntarily withdraw the drug from the market since January due to comparable concerns regarding study integrity. Further compounding the issues, the New England Journal of Medicine retracted the pivotal study's paper in June over these integrity problems. Despite the mounting global pressure, Amgen is actively defending Tavneos, having requested a hearing with the FDA and submitting new data analysis and patient testimony to support the drug's clinical profile and perceived value for patients.

EMA's Decision: Unpacking Tavneos' Questionable Pivotal Data

Across its studied indications, avacopan (Tavneos) has demonstrated a broadly comparable safety profile to standard-of-care regimens, with its most clinically meaningful differentiator being a significant reduction in glucocorticoid-associated toxicity. In the pivotal 52-week ADVOCATE trial, serious adverse events were nearly identical between the avacopan and prednisone taper groups (55.9% vs. 56.1%, respectively, in the cyclophosphamide-receiving subpopulation), suggesting no meaningful difference in overall harm burden. However, avacopan conferred significantly lower glucocorticoid toxicity as measured by the Glucocorticoid Toxicity Index: by week 13, four domains — BMI, glucose tolerance, lipid metabolism, and skin toxicity — favored avacopan, with BMI, lipid metabolism, and skin toxicity remaining significantly better through week 26. No domain favored the prednisone group. This was accompanied by a substantially lower mean glucocorticoid exposure over 26 weeks (1,073 mg vs. 3,192 mg), with reductions of 61% and 49% observed in patients aged 65–74 and ≥75 years, respectively — a clinically relevant finding given the heightened vulnerability of older patients to steroid-related morbidity.

Real-world evidence from a systematic review of 16 studies corroborates the trial-derived safety profile, with serious infection rates of 14% (95% CI: 0.10–0.18) in AAV patients treated with avacopan. Notably, heterogeneity in hepatotoxicity signals was observed across real-world cohorts, with this risk appearing particularly pronounced in Japanese populations — a finding that introduces important pharmacovigilance considerations for broader clinical deployment. Variability in glucocorticoid tapering practices across real-world settings also complicates direct cross-study safety comparisons. In the ENT/lung manifestation subgroup and in patients aged 65 and older, adverse event rates remained comparable between treatment arms, reinforcing the consistency of avacopan's tolerability across clinically relevant subpopulations.

Beyond ANCA-associated vasculitis, avacopan's safety data in other indications remains limited but reassuring at this stage of clinical development. In a phase 2 randomized, double-blind, placebo-controlled trial in complement 3 glomerulopathy (N=57), the incidence and nature of adverse events were comparable between avacopan and placebo, with no deaths and no emergent safety signals detected. Similarly, a meta-analysis of randomized controlled trials in moderate-to-severe hidradenitis suppurativa identified no increase in serious adverse events relative to placebo. Taken together, the available evidence positions avacopan as a broadly tolerable agent with a safety profile that is at minimum non-inferior to standard therapy — and potentially advantageous where cumulative glucocorticoid exposure is a primary concern.

Navigating the Treatment Landscape for ANCA-Associated Vasculitis

Current treatment approaches for ANCA-associated vasculitis (AAV) have expanded considerably, yet several persistent limitations continue to challenge clinical teams in achieving durable, well-tolerated remission. The disease's chronic relapsing nature, combined with the toxicity burden of standard immunosuppressive regimens, underscores the need for more refined therapeutic strategies.

• Glucocorticoid-related toxicity: Glucocorticoids remain a cornerstone of AAV management but carry a substantial adverse effect profile that scales with cumulative dose. Mood disturbances and glucocorticoid-induced psychosis tend to emerge early in the treatment course, while adrenal insufficiency typically manifests later. Infection-related adverse events occur consistently throughout treatment, and patients receiving high-dose regimens experience elevated rates of severe infections, weight gain, and steroid-induced diabetes.

• High relapse rates and absence of durable cure: AAV frequently follows a chronic relapsing course, with each relapse driving additional immunosuppressive exposure and compounding toxicity risk. Conventional therapy with glucocorticoids, with or without adjunctive immunosuppressants, is constrained by partial efficacy and a high relapse rate. Critically, current treatment does not achieve drug-free long-term remission, necessitating indefinite maintenance immunosuppression for most patients.

• Progression to end-stage renal disease (ESRD): A significant proportion of patients with ANCA-associated glomerulonephritis progress to ESRD, requiring long-term renal replacement therapy. In pediatric cohorts, approximately half of patients progressed to ESRD at a mean of 13.04 ± 15.83 months post-diagnosis. Independent predictors of non-remission following induction and subsequent ESRD progression include a baseline eGFR <60 ml/min/1.73 m² and hypertension at diagnosis.

• Gaps in real-world clinical guidance: Despite emerging guideline endorsement of newer agents such as avacopan, practical guidance on their integration into routine clinical workflows remains limited. Key unresolved questions include optimal treatment duration, rituximab dosing strategy, and whether maintenance dosing should follow a fixed schedule or be individualized based on B cell reconstitution and ANCA titre dynamics.

• Diagnostic delays: GPA in particular presents with non-specific clinical features, increasing the risk of missed or delayed diagnosis. Given that untreated disease can rapidly progress to renal failure or multiorgan dysfunction, diagnostic delays carry significant consequences for patient outcomes.

Avacopan's Data Integrity Crisis: A Precedent for Pharma

The recent decision by European regulators to revoke the marketing authorization for Amgen's Tavneos (avacopan) sends a powerful, unequivocal message across the pharmaceutical industry: data integrity is paramount. This move, prompted by 'serious breaches' in the pivotal ADVOCATE clinical study, specifically the manipulation of unblinded efficacy data, casts a long shadow over a drug once hailed as a significant advance in treating ANCA-associated vasculitis (AAV).

Avacopan, an oral C5a receptor antagonist, was positioned as a crucial glucocorticoid-sparing therapy. Clinical literature highlighted its potential to achieve non-inferior remission at 26 weeks and, critically, superior sustained remission at 52 weeks compared to standard glucocorticoid regimens, while also reducing glucocorticoid-related toxicity and improving renal recovery in AAV patients. These benefits were particularly appealing given the severe side effects associated with long-term glucocorticoid use. The drug's initial approval by both the FDA and EMA in 2021, and its subsequent inclusion in the 2024 KDIGO guidelines as an alternative to glucocorticoids for remission induction, underscored its perceived value.

However, the alleged data manipulation directly undermines the credibility of these findings, especially the 52-week superiority claim that was a key differentiator. The retraction of the study's paper by the New England Journal of Medicine further solidifies the scientific community's rejection of the compromised data. For Amgen, which acquired ChemoCentryx for $3.7 billion largely on the strength of avacopan, the financial and reputational fallout is immense. This event serves as a stark reminder of the critical importance of robust due diligence in M&A activities and the severe consequences of failing to uphold the highest standards of clinical trial conduct.

Beyond the immediate impact on Amgen, this situation creates a significant void in the AAV treatment landscape. While real-world data has emerged, generally supporting avacopan's efficacy and highlighting its role in diverse patient subgroups, questions regarding long-term safety, optimal glucocorticoid co-administration, and specific safety signals like hepatotoxicity in certain populations remain. The regulatory actions underscore that even promising therapies, if built on a foundation of compromised data, cannot withstand scrutiny. This precedent will undoubtedly lead to heightened vigilance from regulatory bodies and a renewed focus on transparency and integrity throughout the drug development lifecycle.